SECURITIES AND EXCHANGE COMMISSION Washington D.C. 2054

                                    FORM 10-Q

                   QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934



For Quarter Ended September 30, 1996           Commission File Number 2-94117-D


                               ECLIPSE CORPORATION
                                 _____________
             (Exact name of registrant as specified in its charter)


COLORADO
                                                                 84-0867911
(State or other jurisdiction of                               (I.R.S. Employer
 incorporation or organization)                             Identification No.)


2   North Cascade Avenue, Suite 330, Colorado Springs, Colorado      80903
--------------------------------------------------------------------------
(Address of principal executive offices)                         (Zip code)


Registrant's telephone number, including area code    (719) 520-1800

                         MICROTECH MEDICAL SYSTEMS, INC.
              (Former name, former address and former fiscal year,
                         if changed since last report.)



Indicate by check whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d)  Yes X        No___
of the Securities Exchange Act of 1934 during the pre-
ceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2)
has been subject to such filing requirements for the 
past 90 days.

     Indicate the number of shares  outstanding of each of the issuer's  classes
of common stock, as of the latest practicable date.


                                                 Number of shares outstanding
              Class                                   at November 14, 1996
 -------------------------------------           --------------------------
 Common stock,  $.0005 par value                     73,830,900 shares


FORM 10-Q
3rd QUARTER

<PAGE>

                                      INDEX 
                                                                PAGE

PART I - FINANCIAL INFORMATION

         Item 1.  Financial Statements *

         Balance Sheets - September 30, 1996  (Unaudited)  and
             December 31, 1995                                    3

         Statements of Operations - Three months ended
             September 30, 1996 and 1995 and nine months ended
             September 30, 1996 and 1995 (Unaudited).             4

         Statement of Cash Flows - Nine months ended
             September 30, 1996  (Unaudited)                      5


         Notes to Financial Statements (Unaudited)                6

         Item 2.  Management's Discussion and 
          Analysis (Unaudited)                                    8

PART II - OTHER INFORMATION
         Items 1 through 6.                                       9


         SIGNATURES                                              10

     * The accompanying  financial  statements are not covered by an independent
certified  public  accountant's  report.  


<PAGE>

                                
 Part 1. Financial Information
 Item 1. Financial Statements

                        ECLIPSE CORPORATION
                    Consolidated Balance Sheets
                            (Unaudited)
<TABLE>
<CAPTION>

                                     ASSETS
                                                          September 30, December 31,
                                                                 1996          1995
                                                                -----------------
                                                            (unaudited)
<S>                                                       <C>           <C>
     CURRENT ASSETS
        Cash and cash equivalents .....................   $    21,219   $   506,519
        Marketable securities .........................        52,012       104,065
        Notes receivable - net ........................       674,792          --
        Accrued interest receivable ...................        12,875
        Prepaid expenses ..............................       145,413          --
                                                              -------            
           Total Current Assets .......................       906,311       610,584

     LAND HELD FOR FUTURE DEVELOPMENT .................       713,183          --

     OTHER ASSETS
        Note receivable ...............................       250,000
        Deposit .......................................        10,219          --
        s
        Deferred taxes ................................        53,000        69,000
        Assets of discontinued operations .............         1,500       204,325
                                                                -----       -------

     TOTAL ASSETS .....................................   $ 1,934,213   $   883,909
                                                          ===========   ===========

                LIABILITIES AND STOCKHOLDERS'EQUITY

     CURRENT LIABILITIES
        Current maturities of long-term debt ..........     $ 303,954    $     --
        Accounts payable ..............................       101,609
        Accrued liabilities ...........................        12,958          --
        Current liabilities of discontinued operations         58,443        77,670
                                                               ------        ------
           Total current liabilities ..................       476,963        77,670

     DEFERRED GAIN ON SALE OF BUSINESS ................       168,971          --

     STOCKHOLDERS'EQUITY
        Common stock, 1 00,000,000 shares, $.0005 par value;
           66,580,900 and 59,080,900 shares issued and
           outstanding September 30, 1996 and December 31,
           1995, respectively .........................        36,403        29,540
        Additional Paid in Capital ....................     1,186,450     1,010,605
        Accumulated deficit ...........................        65,426      (233,906)
                                                               ------      -------- 
           Total stockholders' equity .................     1,288,279       806,239
                                                            ---------       -------

     TOTAL LIABILITIES AND STOCKHOLDERS'EQUITY            $ 1,934,213    $  883,909
                                                          ===========    ==========
</TABLE>

                 See accompanying notes to these financial statements.

                                 3

                        ECLIPSE CORPORATION

               Consolidated Statements of Operations
             For Nine Months Ended September 30, 1996
                            (Unaudited)

<TABLE>
<CAPTION>

                                             THREE MONTHS ENDED              NINE MONTHS ENDED
                                                SEPTEMBER 30,                   SEPTEMBER 30,
                                             1996            1995            1996           1995
                                             ---------------------------------------------------
<S>                                   <C>             <C>            <C>             <C>
 NET SALES ........................   $    499,011    $       --     $    499,011    $       --
COST OF GOODS SOLD ................        412,698            --          412,698            --
                                           -------                        -------              
 GROSS PROFIT .....................         86,313            --           86,313            --

OPERATING EXPENSES ................        294,409            --          294,409          50,505
                                           -------                        -------          ------

(LOSS) FROM CONTINUING OPERATIONS .       (208,096)           --         (208,096)        (50,505)

OTHER INCOME (EXPENSES):
   Other expenses .................         (5,466)           --           (5,466)         (2,002)
   Gain on sale of assets .........           --              --             --             6,000
   Interest income (expense), net .         32,947            --           32,947          16,940
   Unauthorized transactions ......        532,437            --          532,437            --

INCOME (LOSS) BEFORE INCOME TAXES
   AND DISCONTINUED OPERATIONS ....        351,822            --          351,822         (29,567)

PROVISION FOR INCOME TAXES ........         27,000            --           27,000          31,000
                                            ------                         ------          ------

INCOME (LOSS) BEFORE DISCONTINUED
   OPERATIONS .....................        324,822            --          324,822         (60,567)

DISCONTINUED OPERATIONS, NET OF TAX           --            22,202        (25,490)        137,183
                                                            ------        -------         -------

NET INCOME (LOSS) .................   $    324,822    $     22,202   $    299,332    $     76,616
                                      ============    ============   ============    ============

INCOME (LOSS) PER SHARE ...........   $     0.0046    $     0.0003   $     0.0042    $     0.0011
                                      ============    ============   ============    ============

WEIGHTED AVERAGE COMMON AND
   COMMON EQUIVALENT SHARES
   OUTSTANDING ....................     70,514,233      66,845,900     70,514,233      69,433,598
                                        ==========      ==========     ==========      ==========

</TABLE>


       See accompanying notes to these financial statements.

<PAGE>
                                

                        ECLIPSE CORPORATION

                     STATEMENTS OF CASH FLOWS

                FOR NINE MONTHS ENDED SEPTEMBER 30,1996 AND 1995
                                   (Unaudited)
<TABLE>
<CAPTION>

                                                    September 30,
                                                        1996     1995
<S>                                             <C>          <C>
 CASH FLOWS FROM OPERATING ACTIVITIES:
   Net Income (Loss) ........................   $   299,332    $    76,616
   Adjustments to reconcile net income to
     net cash from operating activities:
         Depreciation and amortization ......         4,878          4,886
         Gain on sale .......................          (858)          --
         Unauthorized transactions ..........      (532,437)          --
         Deferred taxes .....................        16,000           --
         Accrued interest ...................       (12,875)          --
         Prepaid expenses ...................      (155,632)          --
         Accounts payable ...................       101,609           --
         Accrued liabilities ................         5,273           --
         Changes in assets and liabilities
          related to Discontinued Operations:
            Income tax payable ..............         7,685        (14,100)
            Discontinued Operations .........       201,983        (15,679)
                                                    -------        ------- 

      Net cash provided by (used in)
          operating activities ..............       (65,042)        51,723

CASH FLOWS FROM INVESTING ACTIVITIES:
   Repayments, former president .............       532,437           --
   Purchase notes receivable - net ..........      (674,792)          --
   Purchase certificate of deposit ..........       (50,000)          --
   Proceeds on sale of fixed assets .........       251,000           --
   Land for resale ..........................      (713,183)          --
   Capital expenditures .....................        (1,998)       (22,000)
                                                     ------        ------- 

      Net cash provided by (used in)
          investing activities ..............    (1,188,973)       (22,000)

CASH FLOWS FROM FINANCING ACTIVITIES:
   Proceeds from long-term debt, net ........       303,954           --
   Notes receivable assigned for
          purchase of land ..................       230,000           --
   Stock issued for purchase of land ........       166,207           --
   Stock options exercised ..................        16,501           --

      Net cash provided by (used in)
          financing activities ..............       716,662           --
                                                    -------             

      Net increase (decrease) ...............      (537,353)        29,723

CASH AT BEGINNING OF PERIOD .................       610,584        509,400
                                                    -------        -------

CASH AT END OF PERIOD .......................   $    73,231    $   539,123
                                                ===========    ===========
</TABLE>

       See accompanying notes to these financial statements.

<PAGE>
                                 

                               ECLIPSE CORPORATION
                          NOTES TO FINANCIAL STATEMENTS
                                  (Unaudited)




1.  GENERAL:
------------


     ECLIPSE  CORPORATION  (the Company) has elected to omit  substantially  all
other notes to the  financial  statements.  These interim  financial  statements
should be read in conjunction  with the Company's  annual report and report Form
10-KSB for the year ended December 31, 1995.

2.  UNAUDITED INFORMATION:
--------------------------

     The  information  furnished  herein was taken from the books and records of
the Company without audit.  However,  such information  reflects all adjustments
(consisting only of normal recurring  adjustments)  which are, in the opinion of
management,  necessary to reflect properly results of interim periods presented.
The  results  of  operations  for the  periods  presented  are  not  necessarily
indicative of the results to be expected for the year.

3.  STOCKHOLDERS EQUITY:
------------------------

     In February 1996 the Board of Directors  granted  3,000,000  options to the
Company's two board members.  The options are  exercisable at $.02 per share for
five years.

4.  DISCONTINUED CONTINED OPERATIONS:
-------------------------------------

     As part of the sale of common stock by Kilgore, the Company entered into an
asset purchase agreement dated June 27, 1996,  pursuant to which the Company has
agreed  to  sell,  subject  to  shareholder  approval,   its  medical  test  kit
manufacturing  operations,  including all licenses,  inventories,  and operating
assets to Kilgore for $251,000. In payment for the assets,  Kilgore will deliver
$1,000 in cash and a note for  $250,000.  The note will bear  interest  at prime
plus  1%,  and  will  be due and  payable  on June 1,  2001.  The  note  will be
collateralized  by Kilgore's  options and certain other collateral paper held by
Kilgore.

     As the Company intends to divest itself of the medical test kit operations,
such  operations  and related  assets and  liabilities  have been  reflected  as
discontinued  operations in the accompanying  financial statements.  Income from
the medical test kit manufacturing operations from June 12, 1996 (effective date
of the sale), have been classified as discontinued  operations.  Such amount has
been  immaterial  through June 30, 1996. The gain from the sale will be deferred
until the note receivable is collected.

     The  sale  of  the  medical  test  kit   operations  was  approved  by  the
shareholders at the annual meeting held on October 10, 1996.

6.  SUBSEQUENT EVENT:
---------------------

     Subsequent  to September 30, 1996,  the Company  entered into the following
the following transactions for the following purposes:

     * Purchased  approximately  30 platted and 25  unplatted  lots from Glacier
Valley Holding Corporation for a consideration of $700,000 consisting assignment
of negotiable  instruments  and contracts of face value of $230,000 and issuance
of 6,250,000 shares of restricted  common stock in the Company.  The transaction
has been booked as of September 30, 1996, the date of the purchase contract. The
transaction was closed October 10, 1996.

     * Issued 1,000,000 shares of restricted common stock to former director and
president  protem Charles L. Diehl pursuant to preexisting  stock option granted
December 11, 1992 by the previous  Board of Directors in exchange for payment of
$1,000.00.

     * The Company  pursuant to  shareholder  approval at their October 10, 1996
meeting  changed  its name from  Microtech  Medical  Systems,  Inc.,  to Eclipse
Corporation effective November 1, 1996.

     * The  Company's  shareholders  at the  October  10,  1996  annual  meeting
approved the sale of the Company's medical test kit  manufacturing  operation to
its former  president and employee,  Jerry G. Kilgore under  previous  contract.
Under the  agreement,  the  Company  has agreed to pay  certain  benefits to Mr.
Kilgore of approximately $55,000.




<PAGE>
                               ECLIPSE CORPORATION
                     MANAGEMENT'S DISCUSSION AND ANALYSIS OF

                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS
                                   (Unaudited)

General:
--------

     The Company's  financial  condition and results of operations  are directly
affected by the following transactions.

     The  Company  has agreed to sell,  subject  to  shareholder  approval,  its
medical test kit manufacturing operations,  including all licenses, inventories,
and fixed  assets to Kilgore for a note of $250,000,  plus $1,000 in cash.  This
Following  shareholder  approval,  this  transaction  will be  closed in the 4th
quarter.

     As the Company intends to divest itself of the medical test kit operations,
such  operations  and related  assets and  liabilities  have been  reflected  as
discontinued operations in the accompanying financial statements.

     The Company  contracted with Glacier Valley Holding  Corporation  September
30, 1996 to purchase a portion of the  Community  at Bear Creek,  a modular home
subdivision  located  in  Colorado  Springs,  Colorado.  The real  estate  under
contract  consists of  approximately  30 platted  and 25  unplatted  lots.  This
transaction  was closed  October 10, 1996,  and is  reflected  on the  Company's
balance sheet as of September 30, 1996.

Financial Condition
-------------------


     As of September 30, 1996, the Company's  working capital was  approximately
$429,000,  a decrease of  approximately  $104,000  from  December 31, 1995.  The
decrease is primarily attributable to the following:



     * Assumption of short-term  debt of $304,0000 as part of the acquisition of
the Community at Bear Creek.

     * $65,000 per month for  services  provided  by an entity  owned by Control
Group commencing July 1996 under a management services contract.

     * $450,000  to purchase a $500,000  mortgage  note  receivable  due from an
unaffiliated company.  This note was previously held by a public company,  which
is managed by the Control Group.

     * $200,000  to  purchase  $208,000  mortgage  note  receivable  due from an
affiliated company.

Result of Operations:
---------------------

     As the  Company's  Board of Directors  has decided to sell the medical test
kit  manufacturing  business,  the statement of operations  has been restated to
reflect  these  operations  as  discontinued  operations.  The  other  remaining
operating  expenses relate  primarily to  professional  fees paid by the Company
associated with being a public entity.

     Discontinued  operations  represent income through June 12, 1996 related to
the prior medical test kit manufacturing operations. Income after June 12, 1996,
which has not been  significant,  related to the medical  test kit  business has
been  retained by Kilgore.  The gain will be deferred on the sale to the medical
business to Kilgore,  until cash is  received  on the  underlying  note given by
Kilgore as  consideration  of the  purchase  of the  business.  The note will be
secured by a Security and Pledge Agreement.

     Income tax expense differs from the expected Federal income tax rate due to
recovery of the valuation  allowance  previously provided on deferred tax assets
related to the allowance  for amounts  previously  due from  Kilgore.  


PART II -OTHER INFORMATION 
---------------------------

Item 1 Through 5 - No response required..


Item 6 -  Exhibits and reports on Form 8-K.

     (a) Exhibits 27* Financial Data Schedule.
         
     (b)  Reports  on Form 8-K A Form 8-K was filed  August 26,  1996  regarding
management change.

<PAGE>


                                    SIGNATURE




     Pursuant to the  requirements  of the  Securities and Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.




                               ECLIPSE CORPORATION
                               -------------------
                                  (Registrant)




DATE:           8/16/96              BY: /s/ Kenneth M. Cahill
                                         KENNETH M. CAHILL, PRESIDENT

DATE:           8/16/96              BY: /s/ J. Royce Renfrow
                                         J. ROYCE RENFROW, SECRETARY


DATE:          8/16/96               BY: /s/ James A. Humpal
                                         JAMES A. HUMPAL, TREASURER
                                         Principal Financial Officer